The Pacific Northwest (PNW) Prostate Cancer SPORE continuation grant represents a coordinated effort of four institutions with established programs and strengths in translational prostate cancer research including basic, clinical, and population sciences as well as career development: 1) the Fred Hutchinson Cancer Research Center (FHCRC);2) the University of Washington (UW) and its affiliated institutions;3) the University of British Columbia and the Prostate Centre of Vancouver General Hospital (UBC);and 4) Oregon Health and Science University (OHSU). These Seattle-, British Columbia- and Portland-based institutions have large multidisciplinary teams of investigators and laboratories dedicated to prostate cancer research and a history of working closely together within this larger milieu. The respective teams of clinicians and researchers at these institutions bring considerable scientific depth, breadth, creativity, and vision required for confronting the most challenging problems blocking progress in our ultimate goal of reducing the morbidity and mortality associated with prostate cancer. This SPORE proposal enlarges the blueprint for a well-built, distinctive and coordinated translational prostate cancer research effort spanning the entire PNW. All participating institutions have made substantial commitments toward supporting the SPORE and its innovative, translational projects: 1) Molecular predictors of prostate cancer progression and mortality;2) Targeting LSD1 in prostate cancer;3) Targeting SEMA3C in castration resistant prostate cancer;4) Clinical development of therapeutic strategies targeting damage responses in the prostate tumor microenvironment;and 5) Exploiting mechanisms of response and resistance to next generation androgen pathway antagonists. We also propose four Cores to support these projects: 1) Leadership and administration;2) Biospecimens;3) Biostatistics;and 4) Clinical research. In addition, we propose a Developmental Research Program and a Career Development Program that will significantly embellish and strengthen the translational goals of our prostate cancer research program and expand opportunities for engaging young as well as established investigators in our multidisciplinary environment.
Prostate cancer (PC) is a major cause of cancer incidence and mortality in US men. This year alone 240,890 men will be diagnosed and 33,720 will die of the disease;and the annual number of men dying from PC is increasing. This highlights the urgent need for translational PC research to uncover the underlying genetic and genomic factors and pathways that drive PC toward its lethal phenotype, including resistance to therapy.
|Chalfin, Heather J; Glavaris, Stephanie A; Malihi, Paymaneh D et al. (2018) Prostate Cancer Disseminated Tumor Cells are Rarely Detected in the Bone Marrow of Patients with Localized Disease Undergoing Radical Prostatectomy across Multiple Rare Cell Detection Platforms. J Urol 199:1494-1501|
|Inoue, Lurdes Y T; Lin, Daniel W; Newcomb, Lisa F et al. (2018) Comparative Analysis of Biopsy Upgrading in Four Prostate Cancer Active Surveillance Cohorts. Ann Intern Med 168:1-9|
|Cheng, Heather H; Plets, Melissa; Li, Hongli et al. (2018) Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer. Prostate 78:121-127|
|Levesque, Christine; Nelson, Peter S (2018) Cellular Constituents of the Prostate Stroma: Key Contributors to Prostate Cancer Progression and Therapy Resistance. Cold Spring Harb Perspect Med 8:|
|Barnard, Monique; Quanson, Jonathan L; Mostaghel, Elahe et al. (2018) 11-Oxygenated androgen precursors are the preferred substrates for aldo-keto reductase 1C3 (AKR1C3): Implications for castration resistant prostate cancer. J Steroid Biochem Mol Biol 183:192-201|
|Ganaie, Arsheed A; Beigh, Firdous H; Astone, Matteo et al. (2018) BMI1 Drives Metastasis of Prostate Cancer in Caucasian and African-American Men and Is A Potential Therapeutic Target: Hypothesis Tested in Race-specific Models. Clin Cancer Res 24:6421-6432|
|Schweizer, Michael T; Haugk, Kathleen; McKiernan, Jožefa S et al. (2018) A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer. PLoS One 13:e0198389|
|Peacock, James W; Takeuchi, Ario; Hayashi, Norihiro et al. (2018) SEMA3C drives cancer growth by transactivating multiple receptor tyrosine kinases via Plexin B1. EMBO Mol Med 10:219-238|
|Pollan, Sara G; Huang, Fangjin; Sperger, Jamie M et al. (2018) Regulation of inside-out ?1-integrin activation by CDCP1. Oncogene 37:2817-2836|
|Wu, Yi-Mi; Cie?lik, Marcin; Lonigro, Robert J et al. (2018) Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer. Cell 173:1770-1782.e14|
Showing the most recent 10 out of 400 publications